Press Room

News / May 06, 2021

Science Turnaround - Case Studies

Case Studies presented by our scientists: how alternative scenarios accelerated progress and improved results allowing our clients’ products to perform better.

Science Turnaround - Case Studies | Hovione

Welcome to the new “Science Turnaround” Series

Our multinational team partners with global customers to help deliver lifesaving and life changing medicines for patients all over the world. Most of the projects we are involved in are complex and challenge us to innovate in order to allow our clients’ products to perform better. 

In this new compilation of Case Studies presented by our scientists, we share how Hovione’s multi-disciplinary teams’ expertise, scientific rigor and out-of-the-box thinking allowed us to see alternative scenarios, accelerating progress and improving results.

 

Click on the image to play the video

Case Study - Enabling lean manufacturing with Process Analytical Technologies (PAT) | Hovione

 

Case Study #6 - “Enabling lean manufacturing with Process Analytical Technologies (PAT)"

In this case study, Ricardo Sousa explains how a 20h bottleneck was eliminated by replacing a loss on drying method with NIR, decreasing the stocking time to 5 hours.

Case Study - De-risking scale-up of DPI formulations | Hovione

 

Case Study #5 - “De-risking scale-up of DPI formulations”

In this case study, João Pereira and Beatriz Fernandes explain how to approach the scale-up of DPI formulations from lab to commercial scale by maintaining scale-independent blending parameters and the capsule filling mechanism, avoiding impact on processability and final product performance. 

Case Study - Hazardous Chemistry at High Temperature | Hovione

 

Case Study #4 - “Hazardous Chemistry at High Temperature”

In this case study, Rudi Oliveira explains how a hazardous chemical process was approached and how continuous flow was applied to achieve a safer and more efficient process at scale.

Case Study - Understanding crystallization | Hovione

 

Case Study #3 - "Understanding crystallization"

In this case study, Filipe Vultos and Liliana Silva explain the approach taken to study the physical stability of a multicomponent amorphous solid dispersion formulation with the aim of achieving a better understanding of the crystallization events occurring during stability studies.

Case Study - Reduction of QC burden | Hovione

 

Case Study #2 - "Reduction of QC burden"

In this case study, André Cruz explains how an analytical bottleneck, that resulted from a combination of a time-consuming analytical technique with a process that involved high throughput of samples, was approached and how Chemometrics allied with Near infrared (NIR) spectroscopy were applied to achieve a faster analytical response that potentiate the increase of productivity for both QC and Production areas.

Case Study - In water we go | Hovione

 

Case Study #1 - “In water we go”

In the first case study, Susana Lucas explains how a multistep chemical process was approached toward a new synthetic route to achieve an efficient and highly sustainable one-pot scalable process.



 



 



 

Wondering if your projects can achieve better results this year?

 

Contact our experts today



 



 



 



 



 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026